Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fifth US Biosimilar To Herceptin Launched By Merck

Ontruzant Biosimilar Available For All Eligible Indications

Executive Summary

Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.

You may also be interested in...



Roche: US Biosimilar Impact Worse Than Expected And ‘Pretty Much Like Europe’

Roche was forced to revise its forecasts for biosimilar competition last year, but even an upward revision of CHF1bn fell short as biosimilar sponsors stole a march in the US at a level that caught the originator by surprise.

US Biosimilars See A Banner Year Despite Few Approvals

With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.

Samsung Bioepis To Present Follow-Up Trastuzumab Data

Four years after initiating its comparative trastuzumab study, Samsung Bioepis has presented positive data that the firm hopes will help build confidence in the use of biosimilars for prescribers and patients. Meanwhile, the company also has good news for its SB11 ranibizumab biosimilar.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel